EWING SARCOMA: FEATURES OF LYMPHOGENOUS METASTASIS AND PROGNOSTIC FACTORS

Background. Lymphogenous metastasis in Ewing sarcoma is a relatively rare and poorly studied event associated with aggressive clinical course and poor prognosis. Until now, no risk factors for lymphogenous metastasis in patients with Ewing sarcoma are reported.

The purpose of the study was to evaluate tumor characteristics as predictors for lymphogenous metastasis and to create a mathematical model for assessing the risk of developing lymph node metastases in patients with Ewing sarcoma.

Material and Methods. Clinical characteristics of the tumor were studied in 88 patients with Ewing sarcoma: in 8 patients with lymphogenous metastasis and in 80 patients having no lymphogenous metastasis. The primary tumor in all patients with lymphogenous metastasis was found to have an extraskeletal origin. Morphological and immunohistochemical characteristics of the tumor were studied in 31 patients with Ewing sarcoma: in 8 patients with lymphogenous metastasis and in 23 patients without lymphogenous metastasis.

Results. Statistical analysis and comparative evaluation of the characteristics of the immunophenotype and histological pattern of the tumor in the two studied groups showed significant differences regarding several of them: the structure of nuclear crowding (fusion of nuclei), focal hemorrhages, nuclear normochromasia, and positive expression of cytokeratins by tumor cells. The above signs (except for nuclear normochromasia) were the basis for creating a mathematical model capable of predicting the risk of lymphogenous metastases in Ewing sarcoma.

Conclusion. The revealed association with lymphogenous metastasis of cytokeratin expression can be considered as indirect confirmation of the pathogenetic significance of the mesenchymal-epithelial transition in the mechanism of lymphogenous metastasis.

1. Fletcher C.D.M., Bridge J.A., Hogendoorn P.C.W., Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. IARC: Lyon, 2013. 468 p.

2. Unni K.K., Inwards C.Y. Dahlin’s bone tumors: General aspects and data on 10,165 cases. 6th ed. 2010. Р. 402.

3. Sahin K., Bayram S., Salduz A. Calcaneal Ewing’s Sarcoma With Skip Metastases to Tarsals and Lymph Node Involvement: A Case Report. J Foot Ankle Surg. 2018 Jan Feb; 57(1): 162–166. doi: 10.1053/j.jfas.2017.07.002.

4. Vázquez A.C., Flores P.G., Chilla Á.H. Involvement of Mediastinal Lymph Nodes by Ewing’s Sarcoma. Arch Bronconeumol. 2017 Apr; 53(4): 215–216. doi: 10.1016/j.arbres.2016.08.003.

5. Pinto A., Dickman P., Parham D. Pathobiologic Markers of the Ewing Sarcoma Family of Tumors: State of the Art and Prediction of Behaviour. Sarcoma. 2011; 2011: 856190. doi: 10.1155/2011/856190.

6. Devi A. Extraskeletal Ewings sarcoma of the paravertebral region with lymph node metastasis. University Journal of Pre and Para Clinical Sciences. 2016. 2(5): 1–5. doi: 10.1016/j.canlet.2006.12.009.

7. Applebaum M.A., Worch J., Matthay K.K., Goldsby R., Neuhaus J., West D.C., DuBois S.G. Clinical Features and Outcomes in Patients with Extraskeletal Ewing Sarcoma. Cancer. 2011 Jul 1; 117(13): 3027–32. doi: 10.1002/cncr.25840.

8. Llombart-Bosch A., Machado I., Navarro S., Bertoni F., Bacchini P., Alberghini M., Karzeladze A., Savelov N., Petrov S., Alvarado-Cabrero I., Mihaila D., Terrier P., Lopez-Guerrero J.A., Picci P. Histological heterogeneity of Ewing’s sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Arch. 2009 Nov; 455(5): 397–411. doi: 10.1007/s00428-009-0842-7.

9. Loverro G., Resta L., Di Naro E., Caringella A.M., Mastrolia S.A., Vicino M., Tartagni M., Schonauer L.M. Conservative Treatment of Ewing’s Sarcoma of the Uterus in Young Women. Case Rep Obstet Gynecol. 2015; 2015: 871821. doi: 10.1155/2015/871821.

10. Machado I., Navarro S., Lopez-Guerrero J.A., Alberghini M., Picci P., Llombart-Bosch A. Epithelial marker expression does not rule out a diagnosis of Ewing’s sarcoma family of tumours. Virchows Arch. 2011 Oct; 459(4): 40914. doi: 10.1007/s00428-011-1138-2.

11. Arpaci E., Yetisyigit T., Seker M., Uncu D., Uyeturk U., Oksuzoglu B., Demirci U., Coskun U., Kucukoner M., Isıkdogan A., Inanc M., Alkis N., Ozkan M. Prognostic factors and clinical outcome of patients with Ewing’s sarcoma family of tumors in adults: Multicentric study of the Anatolian Society of Medical Oncology. Med Oncol. 2013 Mar; 30(1): 469. doi: 10.1007/s12032-013-0469-z.

12. Landuzzi L., De Giovanni C., Nicoletti G., Rossi I., Ricci C., Astolfi A., Scopece L., Scotlandi K., Serra M., Bagnara G.P., Nanni P., Lollini P.-L. The Metastatic Ability of Ewing’s Sarcoma Cells Is Modulated by Stem Cell Factor and by Its Receptor c-KIT. Am J Pathol. 2000 Dec; 157(6): 212331. doi: 10.1016/S0002-9440(10)64850-X.

13. Pandure M., Karle R., Angerkar N., Kachewar S. Case Report Ewing’s Sarcoma/Primitive Neuroectodermal tumor of plantar aspect of foot (soft tissue) in adult female: A case report. Int J Biomed Adv Res. 2014. 05 (12): 654–657. doi: 10.7439/ijbar.

14. Applebaum M.A., Goldsby R., Neuhaus J., DuBois S.G. Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvement. Pediatr Blood Cancer. 2012 Oct; 59(4): 617–20. doi: 10.1002/pbc.24053.

15. Vasiliev N.V. Lymph node metastasis of osteosarcomas. Archive of Pathology. 2016; 78(4): 58–64. (in Russian).

16. Leavey P.J., Collier A.B. Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther. 2008 Apr; 8(4): 617–24. doi: 10.1586/14737140.8.4.617.

17. Lee Y.T., Moore T.M., Schwinn C.P. Metastasis of sarcomatous lesion in regional lymph node. J Surg Oncol. 1982 May; 20(1): 53–8. doi: 10.1002/jso.2930200113.

18. Hamidi N., Esen B., Kıvrak H., Sertçelik A., Gülpınar Ö. A large and metastatic primitive neuroectodermal tumor of the kidney. Turk J Urol. 2015 Sep; 41(3): 152–4. doi: 10.5152/tud.2015.92653.

19. Huh J., Kim K.W., Park S.J., Kim H.J., Lee J.S., Ha H.K., Tirumani S.H., Ramaiya N.H. Imaging Features of Primary Tumors and Metastatic Patterns of the Extraskeletal Ewing Sarcoma Family of Tumors in Adults: A 17-Year Experience at a Single Institution. Korean J Radiol. 2015 JulAug; 16(4): 783–90. doi: 10.3348/kjr.2015.16.4.783.

20. Miller M.E., Emerson L., Clayton F., Bentz B.G., Data R.E., Salzman K.L., Smith L. M., Yu M.K. Extraosseous Ewing’s Sarcoma. J Clin Oncol. 2007 Oct 20; 25(30): 4845–8.

21. Tan Y., Zhang H., Ma G.-L., Xiao E.-H., Wang X.-C. Peripheral primitive neuroectodermal tumor: Dynamic CT, MRI and clinicopathological characteristics analysis of 36 cases and review of the literature. Oncotarget. 2014 Dec 30; 5(24): 12968–77. doi: 10.18632/oncotarget.2649.

22. Zhang K., Lu R., Zhang P., Shen S., Li X. Askin’s tumor: 11 cases and a review of the literature. Oncol Lett. 2016 Jan; 11(1): 253–256. doi: 10.3892/ol.2015.3902.

23. Cotterill S.J., Ahrens S., Paulussen M., Jürgens H.F., Voûte P.A., Gadner H., Craft A.W. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European intergroup cooperative Ewing’s sarcoma study group. J Clin Oncol. 2000 Sep; 18(17): 3108–14. doi: 10.1200/JCO.2000.18.17.3108.

24. Frank G.A., Zavalishina L.E., Andreeva Yu.Yu. Methods of immunohistochemistry and in situ hybridization in oncomorphology. Moscow, 2009. 14 p. (in Russian).

25. Dabbs D.J. Diagnostic immunohistochemistry: theranostic and genomic. Saunders, 2010. P. 941.

26. De Silva M.V.C., McMahon A.D., Paterson L., Reid R. Identification of poorly differentiated synovial sarcoma: a comparison of clinicopathological and cytogenetic features with those of typical synovial sarcoma. Histopathology. 2003, 43 (3): 220–230. doi: 10.1046/j.13652559.2003.01668.x.

27. Fisher C. Low-grade Sarcomas with CD34-Positive Fibroblasts and Low-Grade Myofibroblastic Sarcomas. Ultrastruct Pathol. 2004 SepDec; 28(5–6): 291–305. doi: 10.1080/019131290882187.

28. Weinreb I., Goldstein D., Perez-Ordoñez B. Primary extraskeletal Ewing family tumor with complex epithelial differentiation: a unique case arising in the lateral neck presenting with Horner syndrome. Am J Surg Pathol. 2008 Nov; 32(11): 1742–8. doi: 10.1097/PAS.0b013e3181706252.

29. Greco M.A., Steiner G.C., Fazzini E. Ewing’s Sarcoma with Epithelial Differentiation: Fine Structural and Immunocytochemical Study. Ultrastruct Pathol. 1988 May-Jun; 12(3): 317–25. doi: 10.3109/01913128809098044.

30. Gu M., Antonescu C. R., Guiter G., Huvos A. G., Ladanyi M., Zakowski M.F. Cytokeratin immunoreactivity in Ewing’s sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. Am J Surg Pathol. 2000 Mar; 24(3): 410–6.

31. Schuetz A.N., Rubin B.P., Goldblum J.R., Shehata B., Weiss S.W., Liu W., Wick M.R., Folpe A.L. Intercellular junctions in Ewing sarcoma/ primitive neuroectodermal tumor: additional evidence of epithelial differentiation. Mod Pathol. 2005 Nov; 18(11): 1403–10. doi: 10.1038/modpathol.3800435.

32. Vakar-Lopez F., Ayala A.G., Raymond A.K., Czerniak B. Epithelial Phenotype in Ewing’s Sarcoma/Primitive Neuroectodermal Tumor. Int. J. Surg. Pathol. 2000. 8 (1): 59–65. doi: 10.1177/106689690000800111.

33. Olsen S.H., Thomas D.G., Lucas D.R. Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol. 2006 May; 19(5): 659–68. doi: 10.1038/modpathol.3800569.

34. Elbashier S.H.A., Nazarina A.R., Looi L.M. Cytokeratin immunoreactivity in Ewing sarcoma/primitive neuroectodermal tumour. Malaysian J Pathol. 2013; 35 (2): 139–145.